International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

SnO_2 Nanoparticles in Cancer Therapy: Advancing Nanotechnology at the Interface of Innovation and Application

Abishek Kumar A. Patil[1], V.S. Mannur[2]

[1]Department of Pharmaceutical Quality Assurance, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar-590010, Belagavi, Karnataka, India
[2]Professor, Department of Pharmaceutical Quality Assurance, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar-590010, Belagavi, Karnataka, India

Abstract

Tin oxide (SnO_2) nanoparticles have emerged as a promising class of metal oxide nanomaterials with significant potential in cancer therapy, especially for skin cancer. Their unique physicochemical properties—such as high surface area, tunable morphology, redox activity, and biocompatibility—enable targeted drug delivery and reactive oxygen species (ROS)-mediated cytotoxicity. This review provides a comprehensive overview of SnO_2 nanoparticle synthesis methods, including chemical and green approaches, and how synthesis affects their biological behavior. We discuss their mechanisms of anticancer activity, including oxidative stress induction, mitochondrial disruption, and enhanced drug delivery. Formulation strategies such as surface functionalization and incorporation into gels or nanocarriers are also examined for improving therapeutic efficacy and selectivity. In vitro and in vivo studies demonstrating their potential in tumor targeting and minimal toxicity to normal tissues are highlighted. Finally, we address the current limitations, regulatory challenges, and future directions for the clinical translation of SnO_2-based cancer nanotherapeutics.

Keywords: Tin oxide nanoparticles, Cancer nanotherapy, Targeted drug delivery, Skin cancer treatment

1. INTRODUCTION

Cancer is one of the most critical global health challenges, responsible for nearly 10 million deaths in 2020 alone. It ranks as the second leading cause of death worldwide and is projected to rise to 28.4 million new cases annually by 2040, according to the World Health Organization.[1] Factors such as urbanization, lifestyle changes, environmental exposure, and increased life expectancy contribute to the growing cancer burden. Skin cancer, in particular, is one of the most commonly diagnosed malignancies and is classified into two main categories: melanoma and non-melanoma skin cancers (NMSCs), which include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).[2]

Melanoma, although less common, is more aggressive and accounts for the majority of skin cancer-related mortality due to its high metastatic potential. In contrast, BCC and SCC are more prevalent but generally less fatal.[3] UV radiation from sunlight is the primary risk factor, but genetics,

immunosuppression, and environmental pollutants also contribute. Treatment approaches for skin cancers include surgical resection, radiotherapy, and chemotherapy. However, these methods suffer from drawbacks such as non-specific cytotoxicity, systemic side effects, and resistance development. Thus, alternative strategies, especially those with enhanced targeting and minimal off-target toxicity, are essential.[4]

Nanotechnology has revolutionized modern medicine, particularly in oncology. It offers novel materials that function at the nanoscale (1–100 nm) and possess properties significantly different from their bulk counterparts.[5] These include enhanced surface area, reactivity, and quantum effects that are particularly beneficial for biomedical applications. In cancer therapy, nanomaterials are used for controlled drug delivery, imaging, diagnostics, and combinational treatments. One of the main advantages of nanomedicine is the ability to deliver therapeutic agents selectively to tumor tissues, thereby minimizing damage to healthy cells. This is achieved through passive targeting mechanisms like the enhanced permeability and retention (EPR) effect, as well as active targeting using ligands or antibodies.[6]

Among the various nanoparticles under investigation, metal oxide nanoparticles (MONPs) have gained attention due to their structural tunability, surface reactivity, and biomedical potential. Zinc oxide (ZnO), titanium dioxide (TiO_2), cerium oxide (CeO_2), and iron oxide (Fe_3O_4) have all demonstrated roles in drug delivery, ROS generation, and imaging. Their ability to interact with biological systems through electrostatic interactions and redox activity makes them valuable in oncology. However, issues such as stability, toxicity, and degradation pathways remain to be fully resolved.[7]

Tin oxide (SnO_2), a relatively newer entrant in the biomedical nanomaterials domain, is an n-type semiconductor with a wide bandgap (~3.6–3.9 eV). Traditionally used in gas sensors, solar cells, and energy devices, SnO_2 has recently attracted interest in the biomedical sciences.[8] Its high surface-to-volume ratio, thermal stability, and low inherent toxicity make it a promising candidate for cancer-related applications. SnO_2 nanoparticles have been shown to exhibit strong oxidative properties, allowing them to induce apoptosis in cancer cells through the generation of reactive oxygen species (ROS).[9]

The biological performance of SnO_2 nanoparticles is largely determined by their physicochemical characteristics, including size, morphology, crystallinity, and surface charge. Smaller particles are typically more reactive and can penetrate cellular membranes more easily.[10] Their large surface area facilitates drug adsorption or conjugation, and their surface can be functionalized with targeting ligands to improve tumor selectivity. These attributes make SnO_2 an ideal candidate for drug delivery systems aimed at selectively destroying tumor tissues while sparing normal cells.[11]

SnO_2 nanoparticles can be synthesized through various techniques, each influencing their properties differently. Chemical methods such as sol-gel, hydrothermal, co-precipitation, and chemical vapor deposition (CVD) offer precise control over particle size and structure but often require harsh chemicals.[12] Alternatively, green synthesis routes using plant extracts, biomolecules, or microorganisms are gaining popularity for being environmentally friendly and biocompatible. These methods avoid toxic reagents and reduce waste, aligning with sustainable nanotechnology goals.[13]

In cancer treatment, SnO_2 nanoparticles function through several mechanisms. One of the most important is ROS generation, which leads to oxidative stress, mitochondrial dysfunction, and eventual cell death in tumor cells. SnO_2 can also disrupt the cell cycle and induce DNA fragmentation. These nanoparticles may act synergistically with chemotherapeutic drugs, enhancing their efficacy and overcoming multidrug resistance. Furthermore, SnO_2 has been explored for its potential in imaging, photothermal therapy, and as a scaffold for theranostic agents.[14]

Skin cancer, due to its external location, is particularly amenable to topical treatments. SnO_2 nanoparticles can be incorporated into gels, creams, or emulsions, facilitating localized drug delivery.[15] This approach minimizes systemic toxicity and enhances the concentration of the active agent at the tumor site. Moreover, the inclusion of SnO_2 in polymeric or lipid-based nanocarriers enhances the penetration of hydrophobic drugs and improves their bioavailability. Studies have shown that SnO_2 nanoparticles exhibit selective cytotoxicity toward melanoma cells while maintaining low toxicity to normal skin fibroblasts.[16]

The integration of SnO_2 with other materials, such as cyclodextrins, polymers, or metal ions, can further improve its therapeutic performance.[17] These composite systems may offer controlled drug release, increased solubility, and multi-modal action. For example, SnO_2-loaded hydrogels or nanosponges can serve as reservoirs for sustained drug delivery, particularly suitable for long-term topical application in skin cancers. Their structural and functional stability also makes them suitable candidates for transdermal delivery systems.

Despite their promise, the clinical translation of SnO_2 nanoparticles faces several hurdles. Comprehensive in vivo studies are required to understand their biodistribution, long-term toxicity, and clearance mechanisms.[18] Regulatory challenges include standardization of synthesis protocols, toxicity assessments, and quality control measures. Moreover, large-scale manufacturing of SnO_2 nanoparticles with consistent quality and reproducibility is a challenge that needs to be addressed before clinical application becomes viable.

In conclusion, SnO_2 nanoparticles present a compelling opportunity in the field of cancer nanomedicine, particularly for skin cancer therapy. Their unique physicochemical properties, ability to generate ROS, and versatility in formulation make them strong candidates for further exploration. While their biomedical use is still in the early stages, ongoing research is steadily uncovering their potential. As the demand for effective, targeted, and low-toxicity cancer treatments continues to rise, SnO_2 nanoparticles could play a crucial role in the next generation of oncological therapies.[19]

2. Physicochemical Properties of SnO_2 Nanoparticles

The efficacy of tin oxide (SnO_2) nanoparticles in biomedical applications, especially in cancer therapy, is deeply rooted in their unique physicochemical characteristics. These include their crystalline structure, particle morphology, surface area, functionalization capabilities, and redox behavior, all of which influence their interaction with biological systems, cellular uptake, and therapeutic potential. Understanding these properties provides insights into how SnO_2 nanoparticles can be engineered for optimized performance in targeted drug delivery and cytotoxic applications.[20]

2.1. Crystallinity and Morphology

SnO_2 nanoparticles typically adopt a rutile-type tetragonal crystal structure, which is the most thermodynamically stable phase under ambient conditions. This phase exhibits octahedral coordination, where each tin atom is surrounded by six oxygen atoms, while each oxygen atom is coordinated to three tin atoms.[21] This 6:3 coordination leads to a highly symmetrical lattice that contributes to the material's thermal and chemical stability. The rutile SnO_2 structure is associated with space group $P4_2/mnm$, with lattice constants a = b = 0.4737 nm and c = 0.3186 nm, which underpins the high photocatalytic and electronic performance observed in various applications.

The morphology of SnO_2 nanoparticles can vary widely depending on the synthesis method, ranging from spherical and cubic to nanorods, nanotubes, and nanoflowers.[22] Techniques such as electrospinning and chemical vapor deposition (CVD) yield highly porous 1D structures like nanowires and nanotubes, which are especially useful in increasing surface area and enhancing reactivity. For instance, the electrospinning technique has been employed to create fibrous SnO_2 structures that exhibit significant porosity and mechanical integrity, features beneficial for sustained drug release and efficient cell membrane penetration.[23]

Moreover, nanostructured SnO_2 materials synthesized through spray pyrolysis, solvothermal, and hydrothermal methods demonstrate diverse morphologies including hollow microspheres and mesoporous tubes.[24] These morphological variations significantly affect surface reactivity, drug loading efficiency, and cellular interaction profiles. For instance, hollow SnO_2 microtubes have demonstrated high photocatalytic activity and stability under UV irradiation, highlighting the influence of structural form on performance.[25]

2.2. Particle Size, Surface Area, and Shape

Particle size and surface area are critical parameters in determining the biological activity of SnO_2 nanoparticles. Smaller particles possess higher surface-to-volume ratios, which enhance their interaction with biological environments and improve cellular uptake. Typically, SnO_2 nanoparticles synthesized via sol-gel or precipitation techniques range between 2.5 to 33 nm in diameter, depending on the capping agents and reaction conditions.[26] This nanoscale dimension allows them to penetrate biological membranes more effectively and accumulate in tumor tissues through the enhanced permeability and retention (EPR) effect.[27]

The specific surface area of SnO_2 nanoparticles is another essential feature impacting their reactivity. Nanoparticles with high surface areas provide more active sites for drug adsorption, biomolecule attachment, or interaction with target cells. For example, green synthesis methods using plant extracts have yielded SnO_2 particles with surface areas as high as 147 m^2/g, which significantly boosts their antimicrobial and potentially anticancer efficacy.[28]

Shape anisotropy also plays a significant role in determining how nanoparticles interact with biological systems. Rod-shaped and tubular SnO_2 particles exhibit enhanced cellular uptake due to their higher aspect ratios, which facilitate better membrane adhesion and internalization. Furthermore, these morphologies often exhibit differential biodistribution and clearance rates, which can be advantageous for designing tailored cancer therapies.[29]

2.3. Surface Functionalization Potential

One of the most powerful attributes of SnO_2 nanoparticles is their amenability to surface modification. The presence of hydroxyl groups on the SnO_2 surface facilitates easy functionalization with a variety of chemical groups, polymers, and biomolecules. This versatility allows for the attachment of targeting ligands such as folic acid, antibodies, or peptides, enhancing the specificity of the nanoparticles toward cancer cells.[30]

Surface functionalization also plays a crucial role in improving colloidal stability, biocompatibility, and circulation time in vivo.[31] Polyethylene glycol (PEG) is commonly used to prevent opsonization and prolong systemic circulation by creating a hydration shell around the nanoparticles.[32] Functionalized SnO_2 can also be conjugated with fluorescent dyes or imaging agents, enabling their use in bioimaging and theranostic applications.

Beyond targeting and imaging, surface engineering can control drug release profiles. Smart coatings responsive to pH, temperature, or enzymes have been applied to SnO_2 systems to enable site-specific and controlled drug release. This is particularly useful in cancer therapy, where the acidic tumor microenvironment can be exploited for selective payload discharge. In one study, SnO_2 nanoparticles coated with biocompatible materials exhibited pH-sensitive drug release that enhanced cytotoxicity against melanoma cells while sparing normal tissue.[33]

2.4. Redox Activity and ROS Generation

The redox properties of SnO_2 nanoparticles are central to their cytotoxic and photocatalytic capabilities.[34] As an n-type semiconductor with a wide bandgap (~3.6–3.9 eV), SnO_2 can absorb UV light and facilitate the generation of reactive oxygen species (ROS) such as hydroxyl radicals, superoxide anions, and hydrogen peroxide. These species can cause oxidative damage to proteins, lipids, and nucleic acids within cancer cells, leading to apoptosis or necrosis.[35]

ROS-mediated cytotoxicity is a widely recognized mechanism through which SnO_2 nanoparticles exert anticancer effects. Upon cellular internalization, these nanoparticles can localize within mitochondria and trigger oxidative stress, resulting in mitochondrial membrane depolarization and activation of the intrinsic apoptotic pathway. This oxidative damage is often more pronounced in cancer cells due to their higher baseline ROS levels and compromised antioxidant defenses, making them particularly susceptible to ROS-based therapies.[36]

Furthermore, doping SnO_2 with transition metals such as Mo, Fe, or Cu can modulate its redox behavior and bandgap, thereby enhancing ROS generation and tuning photocatalytic performance.[37] Doped SnO_2 nanoparticles have demonstrated increased efficacy in degrading environmental toxins and inducing cytotoxic effects in cancer models. These enhancements are often attributed to improved charge separation and extended lifespan of photogenerated electron-hole pairs, which increase ROS production.

Photocatalytic activity is not only useful for direct cancer cell destruction but also for synergistic effects when combined with light-based therapies such as photodynamic therapy (PDT). SnO_2 nanoparticles can act as photosensitizers or carriers for light-activated drugs, enabling dual-mode therapeutic action that improves treatment outcomes and reduces drug resistance.[38]

3. Synthesis Methods of SnO_2 Nanoparticles and Their Influence on Anticancer Efficacy and Cytotoxicity Profiles

The synthesis route plays a pivotal role in determining the physicochemical characteristics and biomedical behavior of tin dioxide (SnO_2) nanoparticles (NPs). Among various synthetic methods developed for metal oxide nanoparticles, techniques such as sol-gel synthesis, hydrothermal/solvothermal processes, chemical vapor deposition (CVD), and co-precipitation stand out due to their efficiency, scalability, and ability to tailor particle features. These methods not only influence the size, crystallinity, morphology, and surface chemistry of SnO_2 NPs but also directly affect their biocompatibility, cellular uptake, reactive oxygen species (ROS) generation capacity, and ultimately their anticancer potential. Understanding the relationship between synthesis strategies and biological performance is vital for optimizing SnO_2 NPs as effective agents in cancer nanomedicine.

3.1. Sol-Gel Synthesis: Tunable Nanostructures with High Homogeneity

The sol-gel technique is one of the most versatile and widely adopted methods for producing SnO_2 nanoparticles with precise control over size, crystallinity, and surface area. This process involves the hydrolysis and polycondensation of metal precursors—typically tin alkoxides or tin chlorides—leading to the formation of a colloidal suspension (sol), which subsequently evolves into a gel-like network. Subsequent drying and calcination yield nanocrystalline SnO_2. The mild reaction conditions, controllable reaction kinetics, and the possibility of doping or functionalizing the gel matrix make this technique attractive for biomedical applications.

In the context of anticancer therapy, sol-gel-derived SnO_2 nanoparticles often exhibit superior homogeneity and uniformity, which are crucial for reproducible biological responses. Uniform particle size enhances cellular uptake and reduces aggregation in physiological media, thereby improving bioavailability and minimizing toxicity to non-target cells. Moreover, the high surface-to-volume ratio of sol-gel-synthesized SnO_2 NPs facilitates the adsorption or conjugation of anticancer drugs and targeting ligands, enhancing therapeutic efficacy. The controlled porosity and crystallinity achievable via sol-gel synthesis can further modulate ROS generation under physiological conditions, which is a key mechanism by which SnO_2 NPs induce apoptosis in cancer cells. However, the presence of residual organic solvents or unreacted precursors may necessitate additional purification to mitigate potential cytotoxic effects in vivo.[39]

3.2. Hydrothermal and Solvothermal Methods: Eco-Friendly and Morphology-Directed Synthesis

Hydrothermal and solvothermal methods are widely regarded as green and efficient routes for synthesizing SnO_2 nanoparticles, especially when seeking well-defined morphologies such as nanorods, nanowires, or hierarchical nanostructures. These methods involve treating metal precursors in aqueous or organic solvents under elevated temperatures and autogenous pressure in a sealed reactor. The closed-system nature allows for high purity and crystallinity with minimal environmental contamination.[40]

A significant advantage of hydrothermal synthesis is the ability to control particle shape and size through parameters like temperature, pH, precursor concentration, and reaction time. This morphological control is highly relevant in cancer therapy, as different nanoparticle geometries exhibit varied cellular internalization rates and biodistribution profiles.[41] For instance, rod-shaped or wire-like SnO_2 nanostructures may show prolonged circulation time and enhanced tumor penetration compared to spherical counterparts. Additionally, the use of biocompatible solvents and capping agents in

hydrothermal or solvothermal systems can yield particles with lower systemic toxicity and better interaction with biological membranes.

Studies have indicated that hydrothermally synthesized SnO_2 NPs can induce selective cytotoxicity in cancer cells by generating ROS, disrupting mitochondrial membrane potential, and activating apoptotic pathways. The eco-friendly synthesis route also avoids the use of hazardous chemicals, reducing the risk of unwanted toxic byproducts. Nonetheless, careful optimization of synthesis parameters is essential to avoid uncontrolled particle growth or phase impurities, which may negatively affect biocompatibility and therapeutic outcomes.[42]

3.3. Chemical Vapor Deposition (CVD): High-Purity Nanomaterials for Targeted Applications

Chemical vapor deposition is a high-temperature, gas-phase method typically employed for the deposition of thin films or nanostructured materials on substrates.[43] In the case of SnO_2, this method involves the thermal decomposition or reaction of volatile tin-containing precursors (such as $SnCl_4$ or $Sn(CH_3)_4$) in the presence of oxidizing agents, leading to the formation of SnO_2 layers or nanostructures on designated surfaces.

CVD offers unparalleled control over stoichiometry, purity, and crystallographic orientation, making it suitable for applications requiring engineered surfaces or device integration, such as sensor-based cancer diagnostics or implant coatings. Although not as commonly used for free-dispersed SnO_2 nanoparticles intended for systemic drug delivery, recent advances have adapted CVD for the production of nanowires or quantum dots with high surface reactivity. Such nanostructures can be functionalized with anticancer agents or biomolecular ligands, offering a platform for both therapeutic and diagnostic (theranostic) applications.[44]

However, the high-temperature requirement and potential use of toxic gaseous precursors in CVD may limit its biomedical applicability unless complemented with stringent purification and surface modification steps. Additionally, CVD-derived particles often require post-synthesis dispersion protocols to render them suitable for biological systems. Despite these challenges, the high crystallinity and phase purity achievable via CVD can enhance photocatalytic ROS generation, a mechanism increasingly exploited in cancer therapy for inducing oxidative stress-mediated apoptosis in malignant cells.[45]

3.4. Co-Precipitation Method: Simplicity and Scalability with Caution

The co-precipitation technique is perhaps the most straightforward and cost-effective method for synthesizing SnO_2 nanoparticles. This process involves the precipitation of tin salts (e.g., $SnCl_2$ or $SnCl_4$) in an alkaline medium, typically using sodium hydroxide or ammonia, followed by aging, filtration, washing, and drying. The major appeal of this method lies in its scalability and minimal equipment requirement, making it suitable for large-scale production of SnO_2 NPs.[46]

Despite its simplicity, co-precipitation suffers from challenges related to particle agglomeration, broad size distribution, and phase heterogeneity, all of which can influence biological behavior. Agglomerated particles may exhibit poor cellular internalization, reduced surface reactivity, and inconsistent cytotoxicity profiles. Furthermore, impurities from unreacted precursors or residual salts can provoke nonspecific toxicity in normal cells. Therefore, post-synthesis treatments such as calcination, surface

functionalization, or dispersion in biocompatible matrices are often necessary to improve the quality of co-precipitated SnO_2 NPs.[47]

Nevertheless, when optimized, co-precipitation can yield bioactive SnO_2 nanostructures capable of inducing dose-dependent cytotoxicity in cancer cells. The ability to incorporate dopants or co-precipitate with other oxides (e.g., ZnO, TiO_2) opens avenues for synergistic anticancer mechanisms, including enhanced ROS generation, pH-sensitive drug release, or photoactivation under near-infrared light. These multifunctional properties enhance the scope of SnO_2 NPs in combination therapies and tumor-targeted nanomedicine.[48]

4.Anticancer Mechanisms of SnO_2 Nanoparticles

Nanotechnology has introduced a new paradigm in cancer therapeutics by enabling the development of nanoscale agents with multifunctional capabilities. Among these, tin dioxide (SnO_2) nanoparticles have emerged as promising candidates owing to their intrinsic redox activity, semiconductor properties, and modifiable surface chemistry.[49] Their therapeutic effects are largely driven by several interconnected mechanisms that selectively target cancer cells while sparing normal tissues to a considerable extent. These mechanisms include the generation of reactive oxygen species (ROS), disruption of mitochondrial function, induction of cell cycle arrest and DNA damage, inhibition of angiogenesis, and synergistic interactions with established chemotherapeutic agents.[50]

4.1. Induction of Oxidative Stress through ROS Generation

The foremost anticancer mechanism exhibited by SnO_2 nanoparticles is the generation of excessive reactive oxygen species (ROS), which include superoxide anions, hydroxyl radicals, and hydrogen peroxide. The redox-active surface of SnO_2 can catalyze the conversion of molecular oxygen into ROS, especially in the intracellular environment where conditions such as acidic pH and elevated levels of glutathione promote redox cycling. Cancer cells, due to their high metabolic activity, already maintain elevated baseline ROS levels, and the additional oxidative stress induced by SnO_2 nanoparticles can push them beyond the threshold for viability.[51]

Upon internalization by cancer cells, typically via clathrin- or caveolae-mediated endocytosis, SnO_2 nanoparticles localize in lysosomes or the cytoplasm, where they initiate ROS generation. The resultant oxidative burst damages cellular macromolecules, including lipids, proteins, and DNA. Lipid peroxidation of the plasma and organelle membranes disrupts membrane integrity and function, whereas protein oxidation leads to the loss of enzymatic activity and structural degradation. DNA damage includes both single- and double-strand breaks, often detected via increased γ-H2AX foci, a hallmark of DNA damage response. The excessive ROS production not only damages the cellular architecture but also activates various pro-apoptotic signaling pathways, including p38 MAPK, JNK, and the intrinsic mitochondrial apoptotic cascade.[52]

The degree of ROS generation and the consequent cytotoxicity are highly dependent on the size, shape, surface area, and crystalline structure of SnO_2 nanoparticles, all of which are influenced by the synthesis method employed. For example, nanoparticles synthesized via the sol-gel method often show greater surface reactivity and homogeneity, which correlates with enhanced ROS-mediated cytotoxic effects. Thus, tuning the physicochemical properties of SnO_2 NPs allows for the modulation of their oxidative stress potential and therapeutic efficacy.[53]

4.2. Mitochondrial Dysfunction and Activation of the Intrinsic Apoptotic Pathway

Following ROS-induced cellular stress, one of the earliest and most critical targets affected within the cancer cell is the mitochondrion. Mitochondria serve not only as energy powerhouses but also as key regulators of apoptotic signaling. SnO_2 nanoparticles, upon entry into the cytoplasm, can localize near mitochondria and induce permeabilization of the mitochondrial membrane. This loss of mitochondrial membrane potential ($\Delta\Psi m$) is a decisive step in the intrinsic apoptotic pathway. As the outer mitochondrial membrane becomes permeable, cytochrome c is released into the cytosol, where it interacts with apoptotic protease activating factor-1 (Apaf-1), forming the apoptosome complex that activates caspase-9.[54]

This initiator caspase then activates downstream effector caspases such as caspase-3 and -7, which are responsible for the execution phase of apoptosis—characterized by DNA fragmentation, chromatin condensation, membrane blebbing, and ultimately cell death. Several studies using JC-1 dye and flow cytometry have demonstrated that treatment with SnO_2 nanoparticles results in a time- and dose-dependent loss of $\Delta\Psi m$, along with elevated levels of cleaved caspase-3 and PARP, confirming the involvement of the mitochondrial pathway.

Interestingly, SnO_2-induced mitochondrial dysfunction appears to be more pronounced in cancer cells than in normal cells, which may be attributed to the already compromised redox state and higher mitochondrial membrane potential in malignant cells. This selectivity enhances the safety profile of SnO_2 nanoparticles, making them attractive candidates for targeted cancer therapy.[55]

4.3. Cell Cycle Arrest and DNA Damage Response

Another key anticancer mechanism of SnO_2 nanoparticles is the induction of cell cycle arrest, which halts the proliferation of cancer cells and facilitates apoptotic signaling.[56] ROS generated by SnO_2 can directly damage DNA, as evidenced by increased levels of 8-oxo-2'-deoxyguanosine (8-oxo-dG) and DNA strand breaks observed via comet assay or TUNEL staining. DNA damage activates checkpoint kinases such as ATM and ATR, leading to phosphorylation of downstream effectors like p53, CHK1, and CHK2.

Activated p53, a central tumor suppressor, upregulates the expression of cyclin-dependent kinase inhibitors such as p21 and p27, which inhibit the activity of CDK-cyclin complexes.[57] This results in arrest of the cell cycle at the G1/S or G2/M phases, depending on the extent and type of DNA damage. Several reports have demonstrated that treatment with SnO_2 nanoparticles results in significant accumulation of cells in the G2/M phase, suggesting inhibition of mitotic progression. This arrest allows time for DNA repair; however, when damage is irreparable, it shifts the balance toward apoptosis.[58]

Moreover, SnO_2 NPs can suppress the expression of oncogenes such as cyclin D1, while upregulating pro-apoptotic genes like Bax and downregulating anti-apoptotic Bcl-2, thus facilitating apoptosis through both cell cycle modulation and mitochondrial pathways. These effects are particularly pronounced in rapidly dividing cancer cells, making SnO_2 NPs suitable for treating aggressive tumors.[59]

5. Applications in Skin Cancer

Skin cancer, particularly melanoma, poses a significant global health burden due to its aggressive nature and high metastatic potential. Conventional treatment strategies, such as surgical excision, radiotherapy, and chemotherapy, though widely used, are associated with limitations including local recurrence, systemic toxicity, and drug resistance. In recent years, nanotechnology-based approaches have gained attention for their ability to enhance drug delivery, increase therapeutic efficacy, and minimize off-target effects. Among the various nanomaterials explored, tin dioxide (SnO_2) nanoparticles (NPs) have demonstrated compelling potential in skin cancer treatment, especially due to their unique physicochemical and biological properties.

5.1. Selective Cytotoxicity toward Melanoma Cells

One of the most promising features of SnO_2 nanoparticles is their selective cytotoxicity toward malignant melanoma cells while sparing healthy skin cells. This selectivity is largely attributed to the intrinsic differences in cellular physiology between cancerous and non-cancerous cells. Melanoma cells are characterized by elevated metabolic rates, altered redox states, and increased basal levels of reactive oxygen species (ROS). SnO_2 nanoparticles, known for their redox-active surfaces, further exacerbate ROS accumulation in these cells, pushing them past the oxidative stress threshold and triggering cell death pathways such as apoptosis.[60]

Several in vitro studies have demonstrated that SnO_2 nanoparticles exhibit higher cytotoxic effects on melanoma cell lines such as A375, B16F10, and SK-MEL-28, compared to normal keratinocytes or fibroblasts. This differential response is reflected in the IC_{50} values, which are significantly lower for melanoma cells. The selectivity is believed to result not only from enhanced ROS production in melanoma cells but also from higher nanoparticle uptake. Malignant cells often overexpress scavenger receptors and endocytic pathways, leading to increased internalization of SnO_2 NPs. Furthermore, melanoma cells tend to exhibit mitochondrial dysfunction and altered apoptotic regulation, making them more vulnerable to oxidative damage induced by SnO_2.

In addition to oxidative stress, SnO_2 nanoparticles can interfere with cell cycle progression in melanoma cells, inducing arrest in the G2/M phase and promoting apoptosis through mitochondrial depolarization and cytochrome c release. These effects are generally less pronounced in non-cancerous cells due to their more robust antioxidant systems and intact cell cycle regulation. Consequently, SnO_2 nanoparticles demonstrate a favorable therapeutic index, which is crucial for clinical translation, especially in topical or localized therapies for skin malignancies.[61]

5.2. Penetration-Enhancing Properties in Topical Formulations

A key advantage of SnO_2 nanoparticles in the context of skin cancer is their utility in topical formulations. The stratum corneum, the outermost layer of the skin, serves as a major barrier to drug penetration. However, nanoscale materials such as SnO_2 particles, particularly when surface-engineered or incorporated into suitable carriers, can significantly enhance drug delivery across this barrier. Their small size, high surface area, and tunable surface charge facilitate interaction with the lipid matrix of the skin, enabling deeper penetration into the epidermis and even the dermis.

Studies have indicated that when SnO_2 nanoparticles are incorporated into hydrogels, liposomes, or creams, their penetration into cancerous skin tissue is significantly improved. These formulations allow sustained and localized release of therapeutic agents, reducing the need for systemic administration and

minimizing side effects. Additionally, SnO_2 nanoparticles can serve as carriers for chemotherapeutic drugs, photosensitizers, or siRNA, thereby enhancing the efficacy of combinatorial therapies.[62]

Moreover, functionalization of SnO_2 nanoparticles with targeting ligands, such as folic acid, hyaluronic acid, or peptides, can increase their specificity for melanoma cells by promoting receptor-mediated uptake. This targeted delivery approach further enhances therapeutic outcomes while limiting off-target toxicity. Unlike conventional chemotherapy, which often lacks tumor specificity, such nanoparticle-based formulations offer precision in treatment, especially for superficial or early-stage melanoma lesions.[63]

In comparative contexts, SnO_2 nanoparticles offer several advantages over conventional metallic nanoparticles like silver (Ag), gold (Au), or zinc oxide (ZnO). While Ag and ZnO nanoparticles are also known for their antimicrobial and anticancer activities, they often exhibit broader cytotoxicity profiles, affecting healthy cells at therapeutic doses. In contrast, SnO_2 nanoparticles exhibit greater biocompatibility and stability, with reduced risk of nonspecific toxicity. Furthermore, gold nanoparticles, although widely researched, are relatively inert and often require surface modification or co-administration with therapeutic agents to exert significant cytotoxicity. SnO_2, by virtue of its intrinsic ROS-generating capability and semiconductor nature, can exert therapeutic effects without requiring external functionalization, although surface engineering can still enhance its performance.[64]

5.3. Potential in Combination with Photodynamic Therapy (PDT)

Another innovative application of SnO_2 nanoparticles in skin cancer lies in their potential use in photodynamic therapy (PDT). PDT is a minimally invasive treatment modality that involves the use of a photosensitizing agent, light of a specific wavelength, and oxygen to generate cytotoxic ROS that destroy cancer cells. However, the efficiency of PDT is often limited by suboptimal delivery of the photosensitizer, poor tissue penetration of light, and hypoxic tumor environments.[66]

SnO_2 nanoparticles can overcome several of these limitations due to their favorable optical and electronic properties. As semiconductors, they exhibit photocatalytic activity under UV or visible light irradiation, generating ROS such as hydroxyl radicals and singlet oxygen. When irradiated with appropriate light sources, SnO_2 NPs can enhance the local oxidative stress within melanoma cells, complementing the effects of traditional photosensitizers. In addition, SnO_2 nanoparticles can be co-loaded or conjugated with known photosensitizers like porphyrins, phthalocyanines, or curcumin to improve their solubility, stability, and cellular uptake.[66]

Furthermore, SnO_2's ability to act as a photosensitizer or photosensitizer-carrier hybrid makes it suitable for dual-function PDT agents. This multifunctionality is especially useful in treating skin cancers, where direct light exposure is feasible and the superficial location of the tumors allows efficient photonic activation. Recent in vivo studies have demonstrated that SnO_2-based nanocomposites, when combined with visible light, can significantly reduce tumor volume in mouse models of melanoma, with minimal damage to surrounding tissues.

In this context, SnO_2 nanoparticles present a compelling alternative or adjunct to traditional PDT formulations. Unlike organic photosensitizers, which are often prone to photobleaching and short-lived ROS generation, SnO_2-based systems are more photostable and can be engineered to provide controlled

and sustained ROS release upon light activation. This makes them particularly advantageous for repeated or prolonged PDT sessions in clinical settings.[67]

6. Formulation Strategies for Enhanced Delivery of SnO_2 Nanoparticles in Skin Cancer

Effective treatment of skin cancers, particularly melanoma, requires precision in both drug delivery and retention at the target site. While SnO_2 nanoparticles (NPs) have shown promise due to their intrinsic cytotoxic and reactive oxygen species (ROS)-generating properties, their clinical utility is significantly enhanced through thoughtful formulation strategies. These strategies not only aim to optimize drug delivery but also address key challenges such as poor solubility, limited skin penetration, and off-target toxicity. As research in nanomedicine progresses, several formulation approaches have emerged that tailor SnO_2 nanoparticles for improved bioavailability, enhanced targeting, and sustained therapeutic action.[68]

6.1. Topical Gels and Creams for Improved Bioavailability and Controlled Release

Among the most direct and patient-compliant methods of administering SnO_2 nanoparticles for skin cancer is the use of topical gels and creams. These semisolid systems are advantageous because they allow localized delivery, bypass systemic circulation, and reduce the potential for systemic side effects. The incorporation of SnO_2 NPs into topical formulations ensures that the active agents are retained at the site of action, i.e., the skin surface and its deeper layers, where melanoma cells typically reside.[69]

Formulating SnO_2 NPs into hydrophilic gels using carbomers, hydroxypropyl methylcellulose (HPMC), or sodium alginate has been shown to facilitate both the uniform dispersion of nanoparticles and prolonged skin contact. These gels create a moist environment that enhances the permeation of SnO_2 through the stratum corneum, especially when applied with permeation enhancers such as dimethyl sulfoxide (DMSO), oleic acid, or ethanol. The slow and sustained release of nanoparticles from these gels minimizes the need for frequent re-application and maintains therapeutic concentrations at the tumor site over extended periods.[70]

In contrast, creams—typically oil-in-water or water-in-oil emulsions—are also used as carriers for hydrophobic nanoparticle formulations. Oil-in-water emulsions, in particular, are favorable for patient comfort and ease of spreading. In these systems, SnO_2 NPs may be incorporated within the oil phase or at the interface, providing both occlusion and delivery to deeper skin layers. Some formulations may further include penetration-enhancing surfactants or emulsifiers that interact with the lipid matrix of the skin to aid in nanoparticle penetration.[71]

6.2. Nanogels and Inclusion Complexes for Solubility and Retention

To address the solubility challenges posed by inorganic nanoparticles, nanogels and inclusion complexes have emerged as effective delivery platforms. Nanogels—cross-linked hydrogel particles in the nanometer size range—are particularly attractive due to their high water content, tunable release profiles, and biocompatibility. SnO_2 NPs can be encapsulated within nanogels based on natural polymers like chitosan, gelatin, or hyaluronic acid, or synthetic polymers like poly(N-isopropylacrylamide) (PNIPAAm). These matrices provide a hydrophilic shell that enhances dispersion in aqueous environments and improves skin retention by adhering to the moist environment of tumor sites.[72]

Moreover, these nanogels can be designed to be responsive to environmental triggers such as pH, temperature, or redox conditions, enabling controlled and stimuli-responsive drug release. For example, acidic pH-responsive nanogels release their contents preferentially in the slightly acidic tumor microenvironment, thus minimizing effects on normal skin tissue. Such smart delivery systems align with the therapeutic need for precision in cancer treatment.

Inclusion complexes, particularly those based on cyclodextrins (CDs), have also gained traction in improving the solubility and stability of nanoparticle systems. Cyclodextrins, due to their hydrophobic inner cavities and hydrophilic outer surfaces, are capable of forming host-guest complexes with poorly soluble molecules. While direct inclusion of SnO_2 NPs into cyclodextrin cavities is limited by particle size, hybrid systems that incorporate SnO_2 with cyclodextrin-conjugated drugs or surface-coatings have demonstrated improved dispersion and loading efficiency. These hybrid structures not only enhance solubility but also promote prolonged residence time on the skin surface, facilitating increased uptake by malignant cells.[73]

6.3.Surface Modification for Targeted Delivery

One of the most critical advances in nanoparticle formulation is the ability to modify the surface of SnO_2 NPs to achieve targeted delivery. Cancer-targeting ligands, such as folic acid, peptides, and polyethylene glycol (PEG), have been employed to improve cellular uptake and reduce non-specific interactions. Folic acid is particularly relevant in melanoma therapy due to the overexpression of folate receptors on melanoma cells. When conjugated to SnO_2 NPs, folic acid facilitates receptor-mediated endocytosis, resulting in enhanced intracellular delivery and therapeutic efficacy.[74]

PEGylation—the attachment of PEG chains to the nanoparticle surface—is another commonly used strategy to increase biocompatibility, reduce immunogenicity, and prolong circulation time (though the latter is more relevant in systemic delivery). In the context of topical or intralesional applications for skin cancer, PEGylation helps to stabilize nanoparticles in the formulation, reduce aggregation, and improve penetration by enhancing the hydrophilic interface with the skin.[75]

Peptide-based targeting has also shown significant promise, especially with peptides that recognize overexpressed integrins, such as RGD (Arg-Gly-Asp) motifs. These peptides bind specifically to integrin receptors that are prevalent on the surface of melanoma and endothelial cells involved in tumor angiogenesis. By attaching RGD peptides to SnO_2 nanoparticles, enhanced specificity and retention at the tumor site can be achieved, which is especially beneficial in advanced or vascularized skin cancers.

In some designs, dual-ligand systems are used—combining PEG for stealth and stability with targeting ligands for cellular specificity. These multifunctional SnO_2-based systems present a versatile platform for integrated diagnosis and therapy, often referred to as “theranostics,” especially when doped with imaging agents or radiolabels.[76]

7.In Vitro and In Vivo Evaluation of SnO_2 Nanoparticles for Skin Cancer Applications

The evaluation of tin dioxide (SnO_2) nanoparticles (NPs) for skin cancer treatment necessitates a thorough understanding of their cytotoxicity, biodistribution, and safety profiles. Both in vitro and in vivo studies are essential to ascertain their therapeutic potential and biocompatibility. This section delves

into the methodologies and findings related to the assessment of SnO_2 NPs in the context of skin cancer, particularly melanoma.[77]

7.1. In Vitro Cytotoxicity Assays

In vitro studies serve as the preliminary step in evaluating the anticancer efficacy of SnO_2 NPs. These studies typically involve assessing the cytotoxic effects of nanoparticles on cancerous and non-cancerous cell lines to determine their selectivity and potency.[78]

7.1.1. MTT Assay

The MTT assay is a colorimetric assay that measures cellular metabolic activity as an indicator of cell viability, proliferation, and cytotoxicity. It involves the reduction of the yellow tetrazolium MTT to purple formazan crystals by metabolically active cells. The amount of formazan produced correlates with the number of viable cells.

Studies utilizing the MTT assay have demonstrated that SnO_2 NPs exhibit dose-dependent cytotoxic effects on melanoma cell lines, such as A375 and B16F10, while exerting minimal toxicity on normal keratinocyte cells. This selective cytotoxicity is attributed to the higher uptake of nanoparticles by cancer cells and their increased susceptibility to oxidative stress induced by reactive oxygen species (ROS) generated by SnO_2 NPs.[79]

7.1.2.Trypan Blue Exclusion Assay

The trypan blue exclusion assay is a straightforward method to assess cell viability based on membrane integrity. Live cells exclude the dye, whereas dead cells absorb it, appearing blue under a microscope. This assay complements the MTT assay by providing a direct count of viable versus non-viable cells.

Application of the trypan blue assay in studies involving SnO_2 NPs has corroborated the findings of the MTT assay, confirming the selective cytotoxicity of these nanoparticles towards melanoma cells while sparing normal skin cells.[80]

7.1.3. Apoptotic Assays

To elucidate the mechanism of cell death induced by SnO_2 NPs, apoptotic assays are employed. These include Annexin V staining, caspase activity assays, and DNA fragmentation analysis. Such assays have revealed that SnO_2 NPs induce apoptosis in melanoma cells through mitochondrial pathways, characterized by the loss of mitochondrial membrane potential, release of cytochrome c, and activation of caspases.[81]

7.2. In Vivo Animal Models

Following promising in vitro results, in vivo studies are conducted to evaluate the therapeutic efficacy and biodistribution of SnO_2 NPs in living organisms. Animal models, particularly murine models, are instrumental in this phase.[82]

7.2.1. Tumor Regression Studies

In vivo tumor regression studies involve the administration of SnO_2 NPs to tumor-bearing mice and monitoring the changes in tumor size over time. These studies have shown that SnO_2 NPs can

significantly inhibit tumor growth in melanoma models, with treated groups exhibiting reduced tumor volumes compared to controls. The antitumor effect is attributed to the induction of oxidative stress and apoptosis in tumor cells by the nanoparticles.[83]

7.2.2. Biodistribution Studies

Understanding the distribution of SnO_2 NPs within the body is crucial to assess their targeting efficiency and potential off-target effects. Biodistribution studies typically involve labeling nanoparticles with fluorescent or radioactive markers and tracking their accumulation in various organs using imaging techniques.

These studies have demonstrated that SnO_2 NPs preferentially accumulate in tumor tissues, likely due to the enhanced permeability and retention (EPR) effect, which allows nanoparticles to passively target tumor sites. Minimal accumulation in vital organs such as the liver and kidneys suggests a favorable biodistribution profile, reducing the risk of systemic toxicity.[84]

8. Histological and Biochemical Toxicity Assessments

To evaluate the safety profile of SnO_2 NPs, histological examinations and biochemical analyses are conducted on major organs post-treatment.

8.1. Histological Analysis

Histological analysis involves the microscopic examination of tissue sections stained with hematoxylin and eosin (H&E) to detect any morphological changes indicative of toxicity. Studies have reported no significant histopathological alterations in the liver, kidneys, or spleen of animals treated with SnO_2 NPs, suggesting minimal organ toxicity.[85]

8.2. Biochemical Markers

Biochemical assessments include measuring serum levels of liver enzymes (e.g., ALT, AST) and kidney function markers (e.g., creatinine, BUN) to detect any functional impairments. These parameters have remained within normal ranges in animals treated with SnO_2 NPs, further supporting their biocompatibility.

9. Comparative Safety Profile

When compared to other metal oxide nanoparticles, such as zinc oxide (ZnO) and copper oxide (CuO), SnO_2 NPs exhibit a more favorable safety profile. ZnO and CuO nanoparticles have been associated with higher levels of cytotoxicity and oxidative stress in normal cells, limiting their therapeutic window. In contrast, SnO_2 NPs demonstrate selective toxicity towards cancer cells while sparing normal cells, making them more suitable for clinical applications.[86]

10. Mechanistic Insights from In Vitro Studies

A detailed examination of the intracellular mechanisms initiated by SnO_2 nanoparticles (NPs) reveals a cascade of molecular events resulting in cancer cell death. Among the most frequently reported mechanisms is the overproduction of intracellular reactive oxygen species (ROS). This ROS generation occurs due to the redox-active surface of SnO_2 NPs, which disrupts cellular homeostasis, leading to

oxidative stress. Elevated ROS levels result in damage to cellular macromolecules, including lipids, proteins, and nucleic acids.[88]

Experimental studies using fluorescence probes such as DCFH-DA have confirmed significant ROS generation in melanoma cells treated with SnO_2 NPs, with a concentration-dependent increase in fluorescence intensity observed after 24 hours of exposure. These effects were markedly reduced in the presence of antioxidants like N-acetylcysteine (NAC), further confirming the ROS-mediated cytotoxic pathway.

Mitochondrial membrane potential ($\Delta\psi m$) analysis using JC-1 dye demonstrated that SnO_2 NPs induce mitochondrial depolarization in melanoma cells, which is an early hallmark of apoptosis. This mitochondrial dysfunction results in the release of cytochrome c into the cytosol, triggering the intrinsic apoptotic pathway. Western blot analysis revealed upregulation of pro-apoptotic proteins such as Bax and cleaved caspase-9 and caspase-3, along with the downregulation of anti-apoptotic Bcl-2 protein. These findings provide compelling evidence for the mitochondrial-mediated apoptosis induced by SnO_2 NPs.

DNA damage was also assessed using the comet assay and γ-H2AX immunofluorescence. Treated melanoma cells exhibited significant DNA strand breaks and increased nuclear foci formation, indicating genotoxic stress. Importantly, these effects were considerably less pronounced in normal keratinocyte cells (HaCaT), underscoring the selectivity of SnO_2 NPs.[89]

10.1. Cell Cycle Arrest

Flow cytometry analysis revealed that SnO_2 NPs induced G2/M phase arrest in melanoma cells. The accumulation of cells in this phase was linked to DNA damage response pathways, including increased expression of p21 and reduced levels of cyclin B1 and CDK1. The resulting inhibition of cell proliferation complements the pro-apoptotic activity of the nanoparticles.[90]

10.2. Synergistic Interactions with Chemotherapeutic Agents

Several studies have explored the potential of SnO_2 NPs to act synergistically with established anticancer drugs. When combined with doxorubicin or paclitaxel, SnO_2 NPs enhanced cytotoxic effects against melanoma cells compared to either agent alone. Combination index (CI) calculations using the Chou–Talalay method yielded CI values <1, indicating synergism. The mechanism underlying this synergy may involve enhanced drug accumulation due to nanoparticle-mediated endocytosis and amplified oxidative damage.[91]

11. In Vivo Tumor Suppression Efficacy

Murine melanoma models (e.g., C57BL/6 mice injected subcutaneously with B16F10 cells) have been extensively used to evaluate the antitumor effects of SnO_2 NPs. In one representative study, tumor-bearing mice were divided into three groups: control (saline), SnO_2 NPs (10 mg/kg), and SnO_2 NPs + paclitaxel (5 mg/kg each). Over a 21-day period, the nanoparticle-treated group exhibited a 45% reduction in tumor volume compared to the control. The combination group showed a synergistic effect, achieving a 70% tumor volume reduction. These effects were statistically significant ($p < 0.01$) and accompanied by increased TUNEL staining in tumor sections, indicative of apoptotic cell death.[92]

11.1. Biodistribution and Targeting Efficiency

To assess the biodistribution, SnO_2 NPs were labeled with near-infrared dyes and tracked via in vivo imaging systems (IVIS). The nanoparticles demonstrated enhanced accumulation at tumor sites 6–24 hours post-injection, which can be attributed to the enhanced permeability and retention (EPR) effect. Fluorescence quantification showed that up to 35% of the administered dose localized in tumor tissues within 24 hours, with minimal retention in the liver (10%) and spleen (8%). PEGylated SnO_2 NPs showed even higher tumor specificity and longer circulation times.[93]

This favorable biodistribution profile minimizes systemic exposure and reduces the risk of off-target effects. Pharmacokinetic analysis revealed a plasma half-life of 6–8 hours for PEGylated SnO_2 NPs compared to 2–3 hours for uncoated nanoparticles, indicating improved stability and circulation time.[94]

12.Toxicity and Biocompatibility Evaluations

12.1. Histopathological Outcomes

Histological examination of vital organs, including the liver, kidneys, lungs, spleen, and heart, revealed no significant pathological changes in SnO_2 NP-treated groups. H&E-stained sections showed normal architecture, absence of inflammatory infiltrates, and no signs of necrosis or fibrosis, even after repeated dosing over 28 days.[95]

12.2. Oxidative Stress Markers in Organs

Although SnO_2 NPs generate ROS in cancer cells, systemic oxidative stress in healthy tissues was not evident. Assays for malondialdehyde (MDA), glutathione (GSH), and catalase in liver and kidney homogenates showed only slight deviations from control levels. These findings suggest that the nanoparticles selectively induce oxidative stress in tumor cells without disturbing systemic redox balance.[96]

12.3. Immunogenicity and Inflammation

Cytokine profiling using ELISA kits for TNF-α, IL-6, and IL-1β showed no significant upregulation in treated mice, ruling out acute inflammatory responses. Additionally, histological sections stained for CD45 and F4/80 showed no major immune cell infiltration in non-tumor tissues. These findings reinforce the biocompatibility of SnO_2 NPs in vivo.

13. Comparison with Other Metal Oxide Nanoparticles

Compared to other metal oxide nanoparticles such as ZnO and CuO, SnO_2 NPs demonstrate several advantages in both efficacy and safety. ZnO NPs, while effective against cancer cells, have been reported to cause significant oxidative damage to normal tissues, especially at higher concentrations. CuO NPs exhibit even higher levels of toxicity due to their strong pro-oxidant activity and tendency to accumulate in organs like the liver and spleen.

In contrast, SnO_2 NPs exhibit a high therapeutic index, attributable to their selective cytotoxicity, controlled ROS generation, and minimal accumulation in healthy organs. Their surface properties also

allow for effective functionalization with targeting ligands (e.g., folic acid, peptides), which further enhances tumor specificity and reduces off-target effects.[97]

14. Implications for Clinical Translation

The comprehensive in vitro and in vivo evaluations of SnO_2 nanoparticles suggest strong potential for clinical application in skin cancer therapy. Their selective action on melanoma cells, favorable biodistribution, and minimal systemic toxicity provide a solid preclinical foundation. Additionally, their compatibility with existing chemotherapeutic agents makes them suitable for combination therapies that may reduce the required doses of conventional drugs and thus mitigate side effects.

Further development efforts should focus on scaling up synthesis under Good Manufacturing Practice (GMP) conditions, validating long-term safety in higher animal models, and preparing for early-phase clinical trials. Regulatory acceptance will require detailed toxicological dossiers, pharmacokinetic data, and efficacy studies under standardized protocols.[98]

14.1. Toxicity and Biocompatibility Concerns of SnO_2 Nanoparticles

The application of tin dioxide (SnO_2) nanoparticles in biomedical fields, particularly in skin cancer therapy, necessitates a thorough understanding of their toxicity and biocompatibility profiles. Several factors influence the interaction of these nanoparticles with biological systems, including particle size, dosage, surface chemistry, and their ability to induce hemocompatibility and genotoxic effects. Moreover, strategies to mitigate off-target effects and enhance clearance are crucial for their safe application. Comparisons with other metal oxide nanoparticles like zinc oxide (ZnO) and titanium dioxide (TiO_2) provide context to evaluate the relative safety and efficacy of SnO_2 nanoparticles.[99]

14.2. Influence of Particle Size, Dose, and Surface Chemistry

Particle Size: The size of nanoparticles significantly affects their biological interactions. Smaller nanoparticles have a higher surface area-to-volume ratio, leading to increased reactivity and potential toxicity. Studies have shown that SnO_2 nanoparticles with smaller sizes exhibit higher toxicity towards bacterial cells due to their enhanced ability to generate reactive oxygen species (ROS) . However, in mammalian systems, the toxicity profile may differ, necessitating specific studies to understand size-dependent effects.[100]

Dose: The concentration of nanoparticles plays a pivotal role in determining their toxicological impact. Higher doses can lead to increased accumulation in tissues, potentially causing adverse effects. It's essential to establish the optimal therapeutic window where the nanoparticles are effective against cancer cells but exhibit minimal toxicity to normal cells.

Surface Chemistry: The surface properties of nanoparticles, including charge, functional groups, and hydrophobicity, influence their interaction with biological membranes and proteins. Modifying the surface of SnO_2 nanoparticles with biocompatible coatings or functional groups can enhance their stability, reduce aggregation, and minimize nonspecific interactions, thereby improving their biocompatibility.[101]

14.3. Hemocompatibility and Genotoxicity Assessment

Hemocompatibility: For nanoparticles intended for systemic administration, it's crucial to assess their compatibility with blood components. Hemocompatibility studies evaluate parameters like hemolysis, platelet aggregation, and coagulation pathways. While specific studies on SnO_2 nanoparticles are limited, it's imperative to conduct comprehensive assessments to ensure they do not adversely affect blood components.[102]

Genotoxicity: The potential of nanoparticles to cause genetic damage is a significant concern. Genotoxicity assessments involve evaluating DNA damage, mutations, and chromosomal aberrations. While some metal oxide nanoparticles have shown genotoxic effects, the genotoxic potential of SnO_2 nanoparticles remains underexplored. Detailed studies using assays like the comet assay and micronucleus test are necessary to determine their safety profile.[103]

14.4. Strategies to Minimize Off-Target Effects and Enhance Clearance

To ensure the safe application of SnO_2 nanoparticles, strategies must be employed to minimize off-target effects and enhance their clearance from the body:

1. *Targeted Delivery:* Functionalizing nanoparticles with ligands that recognize specific receptors on cancer cells can enhance their accumulation at the tumor site, reducing systemic exposure and off-target effects.
2. *Biodegradable Coatings:* Coating nanoparticles with biodegradable polymers can facilitate their breakdown and clearance from the body, minimizing long-term accumulation.
3. *Stimuli-Responsive Systems:* Designing nanoparticles that respond to specific stimuli (e.g., pH, enzymes) present in the tumor microenvironment can ensure controlled release of therapeutic agents, enhancing efficacy and reducing side effects.
4. *Optimizing Physicochemical Properties:* Adjusting properties like size, charge, and hydrophobicity can influence the biodistribution and clearance pathways of nanoparticles, aiding in their safe elimination from the body.[104]

15. Comparisons with ZnO and TiO_2 Nanoparticles

Comparing SnO_2 nanoparticles with other commonly studied metal oxide nanoparticles provides insights into their relative safety and efficacy:

*Zinc Oxide (ZnO) Nanoparticles:*ZnO nanoparticles have been extensively studied for their antimicrobial and anticancer properties. However, they have been associated with higher levels of cytotoxicity and oxidative stress in normal cells, limiting their therapeutic window .

Titanium Dioxide (TiO_2) Nanoparticles:TiO_2 nanoparticles are widely used in various applications, including sunscreens and photocatalysis. While generally considered biocompatible, concerns have been raised about their potential to induce oxidative stress and inflammation upon exposure .

In contrast, SnO_2 nanoparticles demonstrate selective toxicity towards cancer cells while sparing normal cells, making them more suitable for clinical applications. Their ability to generate ROS selectively in cancer cells and their favorable biodistribution profiles contribute to their therapeutic potential.[105]

16. Regulatory and Translational Perspectives on SnO_2 Nanoparticles

The transition of tin dioxide (SnO_2) nanoparticles from laboratory research to clinical use is still in its nascent phase. Although preclinical studies have shown that SnO_2 NPs possess promising anticancer properties with selective cytotoxicity towards malignant cells and reduced toxicity toward normal cells, they have not yet reached human clinical trials. Extensive data from toxicity studies, pharmacokinetics, biodistribution, and efficacy models must be generated before regulatory approval can be considered.[106]

16.1. Current Regulatory Frameworks

The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global regulatory authorities have introduced specific considerations for nanomedicines. These include thorough nanoparticle characterization—covering size, morphology, surface charge, composition, stability, and potential interactions with biological systems. SnO_2 NPs must meet these criteria under Investigational New Drug (IND) applications and follow strict Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) in preclinical and clinical phases.[107]

16.2. Scale-Up and Manufacturing Challenges

Translating bench-scale synthesis to industrial-scale production is a significant challenge for SnO_2 NPs. Batch-to-batch reproducibility must be ensured, and nanoparticle characteristics such as size distribution, surface chemistry, and colloidal stability must be consistent. Additionally, the integration of sterile manufacturing techniques, avoidance of contamination, and development of scalable purification and drying methods are critical to meet quality standards for human use. Regulatory bodies require robust documentation and quality assurance systems throughout the production chain.

16.3. Patient Safety and Product Labeling

Safety evaluations must address acute and chronic toxicity, genotoxicity, immunogenicity, and organ-specific accumulation. Long-term safety data, especially for dermal or systemic applications, are needed. Labeling regulations for nanopharmaceuticals mandate detailed information on the nanoparticle content, dosage, mechanism of action, and potential risks. This helps ensure transparency for healthcare providers and patients alike.[108]

16.4. Ethical Considerations

Ethical issues include patient consent in trials involving nanotechnology, equitable access to advanced therapies, and the environmental impact of nanoparticle production and disposal. Regulatory frameworks also stress the need for transparency regarding the experimental status of SnO_2-based treatments, particularly during early-phase trials. Public engagement, post-market surveillance, and interdisciplinary oversight are encouraged to maintain safety and trust.[109]

17. Future Directions and Challenges in SnO_2 Nanoparticles for Cancer Therapy

The application of tin dioxide (SnO_2) nanoparticles (NPs) in cancer therapy, particularly for skin cancers like melanoma, holds tremendous potential. However, the path to clinical success requires overcoming several challenges related to targeting precision, treatment efficacy, safety, and long-term

biocompatibility. This section explores the future directions and challenges involved in improving SnO_2 nanoparticle-based therapies for cancer treatment.[110]

17.1. Enhancing Targeting Precision via Ligand Modification

The selective targeting of cancer cells while sparing healthy tissue is one of the main challenges of nanoparticle-based therapies. SnO_2 NPs have shown promising selective cytotoxicity towards melanoma cells in vitro, but further optimization of targeting strategies is necessary to improve their clinical efficacy. Surface modification of SnO_2 NPs with specific ligands, such as antibodies, peptides, or small molecules, can help enhance their specificity towards tumor cells.

The functionalization of SnO_2 NPs with ligands that target tumor-associated receptors, such as epidermal growth factor receptor (EGFR), folate receptors, or integrins, can increase the accumulation of nanoparticles at tumor sites via the enhanced permeability and retention (EPR) effect. Additionally, surface coatings like polyethylene glycol (PEG) are commonly used to improve nanoparticle stability and circulation time in the bloodstream, preventing rapid clearance by the immune system. PEGylation, along with ligand targeting, can enhance the therapeutic window by reducing off-target effects and improving nanoparticle uptake by cancer cells.

Moreover, a combination of targeting ligands could further improve specificity. For instance, conjugating SnO_2 NPs with dual-targeting ligands, such as EGFR antibodies and folic acid, could not only target cancer cells but also enhance the delivery of nanoparticles to the tumor microenvironment. Such approaches would allow for more precise delivery of therapeutic agents while minimizing side effects to surrounding healthy tissues.[111]

17.2. Integration with Immunotherapy and Gene Therapy

The integration of SnO_2 NPs with other therapeutic modalities, such as immunotherapy and gene therapy, could significantly enhance their anticancer efficacy. Nanoparticles offer an excellent platform for the delivery of immunomodulatory agents like checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4), cytokines, or immune-stimulating molecules. These agents, when delivered via SnO_2 NPs, could enhance the body's immune response to tumor cells, overcoming immune evasion mechanisms commonly seen in cancers.

In addition, SnO_2 NPs can be combined with gene therapy approaches to further improve therapeutic outcomes. For instance, SnO_2 NPs can be utilized as non-viral vectors for the delivery of therapeutic genes, such as tumor suppressor genes, or for RNA-based therapies like small interfering RNA (siRNA) or short hairpin RNA (shRNA) to silence oncogenes. Such strategies can modify the genetic makeup of tumor cells, making them more susceptible to other forms of treatment. For example, combining SnO_2 NPs with the delivery of p53 tumor suppressor genes could promote cell cycle arrest and apoptosis in cancer cells.

The combination of immunotherapy, gene therapy, and SnO_2 NPs may offer synergistic effects that significantly improve the efficacy of cancer treatment. However, challenges remain in optimizing the co-delivery of these therapies, ensuring that nanoparticles can efficiently deliver both the immunotherapeutic and gene therapeutic agents to the tumor without triggering unwanted immune responses or toxicity.[112]

17.3. Real-Time Imaging and Theranostic Applications

The incorporation of SnO_2 NPs with real-time imaging modalities offers exciting possibilities for theranostic applications—simultaneous diagnosis and therapy. Theranostics provides a platform for personalized medicine by allowing real-time monitoring of tumor response to treatment. SnO_2 NPs can be functionalized with imaging agents such as fluorescent dyes or magnetic markers, allowing for in vivo tracking of nanoparticles and monitoring the progress of therapy.

Fluorescently labeledSnO_2 NPs can be monitored using fluorescence microscopy or in vivo imaging systems (IVIS), providing real-time data on nanoparticle biodistribution and tumor targeting. Such techniques can help identify the most responsive tumors, allowing for adjustments in treatment protocols during therapy. Magnetic SnO_2 NPs, when coupled with magnetic resonance imaging (MRI), enable high-resolution imaging, making it possible to visualize the tumor location and track the release of therapeutic agents from the nanoparticles.

In addition to tracking tumor progression, theranostic applications of SnO_2 NPs can help monitor treatment response, providing immediate feedback on the efficacy of therapy. This real-time monitoring ensures the effective delivery of drugs or other therapeutic agents to the tumor, optimizing the treatment process and minimizing systemic side effects. For example, the simultaneous delivery of chemotherapy drugs, RNA molecules, or immunotherapeutic agents via SnO_2 NPs could be tracked through fluorescence or MRI, ensuring proper drug localization and monitoring the tumor's response.[113]

17.4. Addressing Long-Term Toxicity and Biodegradability

A major challenge in the clinical translation of SnO_2 NPs is the potential long-term toxicity due to nanoparticle accumulation in organs such as the liver, spleen, and kidneys. While SnO_2 NPs have demonstrated relatively low toxicity in in vitro and short-term in vivo studies, their long-term effects on human health remain uncertain. Chronic toxicity is a significant concern for nanomedicines, as the slow clearance of nanoparticles from the body can lead to their accumulation in vital organs, potentially resulting in long-term adverse effects.

To address these concerns, research into the biodegradability and clearance mechanisms of SnO_2 NPs is crucial. Biodegradable surface coatings, such as natural polymers like chitosan or synthetic polymers like PEG, can improve the biocompatibility and clearance of SnO_2 NPs. These coatings can prevent aggregation, enhance circulation time, and enable safer elimination of the nanoparticles from the body. Furthermore, ensuring that SnO_2 NPs degrade into non-toxic byproducts is essential for preventing long-term accumulation in tissues.

Studies on the biodegradation of SnO_2 NPs should include assessments of how the nanoparticles break down in vivo, the nature of their degradation products, and how they are excreted from the body. In addition, long-term follow-up studies are necessary to monitor any delayed toxicity or immune system disturbances that may arise from prolonged exposure to SnO_2 nanoparticles. This data is crucial to determine whether SnO_2 NPs can be safely used for repeated or chronic treatments.[114]

17.5. Comparison with Other Nanoparticles

In the context of cancer therapy, it is important to compare SnO_2 NPs with other widely studied metal oxide nanoparticles, such as zinc oxide (ZnO) and titanium dioxide (TiO_2). These nanoparticles have

been explored for their anticancer properties; however, they have some limitations regarding toxicity, biocompatibility, and stability. ZnO nanoparticles, for example, have been associated with higher levels of cytotoxicity due to the release of zinc ions, which can induce oxidative stress and damage to healthy tissues.

In contrast, SnO_2 NPs exhibit relatively low toxicity and selective cytotoxicity toward cancer cells, making them an attractive alternative for cancer therapy. While TiO_2 NPs have also shown anticancer potential, they are less biodegradable and may present greater long-term safety concerns. SnO_2 NPs, therefore, offer a potentially safer option due to their favorable toxicity profile and ability to selectively target tumor cells while minimizing harm to healthy tissues.

Despite these advantages, SnO_2 NPs must be further investigated in comparison to other nanoparticles to determine their relative efficacy, safety, and clinical applicability. Comparative studies on the biodistribution, toxicity profiles, and therapeutic outcomes of SnO_2, ZnO, and TiO_2 nanoparticles are essential to establish the optimal choice of nanoparticles for specific cancer treatments.[115]

CONCLUSION

SnO_2 nanoparticles have emerged as promising candidates for cancer therapy, offering several advantages in terms of selective cytotoxicity, redox activity, and versatile formulation strategies. As highlighted throughout the discussion, their potential for targeting skin cancers, particularly melanoma, is attributed to their ability to generate reactive oxygen species (ROS) and induce oxidative stress, leading to cell death through mitochondrial dysfunction, apoptosis, and DNA damage. Moreover, SnO_2 NPs exhibit unique properties, including the capacity to penetrate tumor cells more effectively than normal cells, thanks to the enhanced permeability and retention (EPR) effect. This selective targeting capability positions SnO_2 nanoparticles as potential candidates for improving the specificity and efficacy of cancer treatments.

While the in vitro studies have demonstrated the anticancer potential of SnO_2 NPs, the successful translation of these nanoparticles into clinical applications depends on addressing several challenges related to their long-term safety, biocompatibility, and effective targeting. The future of SnO_2-based therapies hinges on advancing surface modifications to improve their stability, circulation time, and tissue-specific targeting. The addition of targeting ligands such as antibodies, peptides, and small molecules, in combination with surface coatings like PEG, can significantly enhance the therapeutic window by directing nanoparticles more precisely to cancer cells, minimizing off-target effects, and reducing systemic toxicity.

Additionally, the integration of SnO_2 NPs with immunotherapy and gene therapy is a promising direction to enhance their anticancer effects. By co-delivering immune-modulating agents or therapeutic genes, SnO_2 nanoparticles could improve the overall therapeutic outcome and potentially overcome resistance mechanisms that tumors develop against conventional treatments. The incorporation of real-time imaging technologies, such as fluorescence and MRI, further augments the utility of SnO_2 NPs, allowing for non-invasive tracking of their biodistribution and therapeutic response, which facilitates personalized treatment approaches and timely adjustments to therapeutic strategies.

Despite these advances, challenges related to the long-term toxicity and biodegradability of SnO_2 NPs remain significant. Ensuring that these nanoparticles can be safely cleared from the body without

causing long-term organ toxicity is critical for their clinical success. Biodegradable coatings and modifications to the nanoparticles' surface could help mitigate this issue, promoting safer elimination from the body and minimizing the risk of accumulation in vital organs. Ongoing studies into the long-term fate of SnO_2 nanoparticles, as well as their potential for inducing chronic toxicity, are necessary to ensure their safety for repeated or prolonged use in clinical settings.

Furthermore, comparisons with other metal oxide nanoparticles, such as zinc oxide (ZnO) and titanium dioxide (TiO_2), demonstrate that SnO_2 NPs offer several advantages in terms of biocompatibility and selective toxicity towards cancer cells. However, a thorough understanding of the relative efficacy and safety profiles of SnO_2 NPs, compared to these other nanoparticles, is essential for determining the most suitable material for specific cancer types and treatment regimens.

In conclusion, SnO_2 nanoparticles represent a promising platform for the development of targeted cancer therapies, offering unique advantages in terms of their selective anticancer activity, versatility in formulation, and potential for integration with other therapeutic modalities. With continued research addressing their toxicity, targeting precision, and long-term safety, SnO_2 nanoparticles may well become key players in the next generation of cancer therapeutics, helping to advance the field of nanomedicine and improve clinical outcomes for cancer patients.

DECLARATION OF COMPETING INTEREST

The authors confirm that there are no known competing financial interests or personal relationships that could have influenced the findings presented in this paper.

ACKNOWLEDGEMENTS

The authors are very thankful to Principal Dr. S. S. Jalalpure and Vice Principal Dr. M. B. Patilfor their support and guidance. Authors are also thankful to Department of PharmaceuticalQuality Assurance for their assistance.

REFERENCES

1. Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022 Sep 1;163(3):649-58.
2. Cives M, Mannavola F, Lospalluti L, Sergi MC, Cazzato G, Filoni E, Cavallo F, Giudice G, Stucci LS, Porta C, Tucci M. Non-melanoma skin cancers: Biological and clinical features. International Journal of Molecular Sciences. 2020 Jul 29;21(15):5394.
3. Roky AH, Islam MM, Ahasan AM, Mostaq MS, Mahmud MZ, Amin MN, Mahmud MA. Overview of skin cancer types and prevalence rates across continents. Cancer pathogenesis and therapy. 2025 Mar 30;3(02):89-100.
4. Hasan N, Nadaf A, Imran M, Jiba U, Sheikh A, Almalki WH, Almujri SS, Mohammed YH, Kesharwani P, Ahmad FJ. Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches. Molecular cancer. 2023 Oct 6;22(1):168.
5. Rokunuzzaman MK. The Nanotech Revolution: Advancements in Materials and Medical Science. Journal of Advancements in Material Engineering. 2024 Jun 19:1-0.

6. Pourmadadi M, Eshaghi MM, Ostovar S, Mohammadi Z, Sharma RK, Paiva-Santos AC, Rahmani E, Rahdar A, Pandey S. Innovative nanomaterials for cancer diagnosis, imaging, and therapy: Drug delivery applications. Journal of Drug Delivery Science and Technology. 2023 Apr 1;82:104357.
7. Alameen AS, Undre SB, Undre PB. Synthesis, dispersion, functionalization, biological and antioxidant activity of metal oxide nanoparticles. Nano-Structures & Nano-Objects. 2024 Sep 1;39:101298.
8. Pinto AH, Nogueira AE, Dalmaschio CJ, Frigini IN, de Almeida JC, Ferrer MM, Berengue OM, Gonçalves RA, de Mendonça VR. Doped tin dioxide (d-SnO2) and its nanostructures: Review of the theoretical aspects, photocatalytic and biomedical applications. Solids. 2022 Jun 2;3(2):327-60.
9. Ahamed M, Akhtar MJ, Khan MM, Alhadlaq HA. SnO2-doped ZnO/reduced graphene oxide nanocomposites: synthesis, characterization, and improved anticancer activity via oxidative stress pathway. International Journal of Nanomedicine. 2021 Jan 8:89-104.
10. Elamin NY, Indumathi T, Kumar ER. Evaluation of physicochemical and biological properties of SnO2 and Fe doped SnO2 nanoparticles. Ceramics International. 2023 Jan 15;49(2):2388-93.
11. Chandrasekaran K, Kokkarachedu V, Sisubalan N, Vijayan A, Hendry Moses P, Edison Raj Godwin P, Kelvin Adaikalam C, Gowri S, Jason Mathews J, Haja Hameed AS, Ebenezar J. Exploring the medical applications of SnO2 nanomaterials: antimicrobial, antiviral, and anticancer therapies. InNanoparticles in Modern Antimicrobial and Antiviral Applications 2024 Feb 28 (pp. 227-242). Cham: Springer International Publishing.
12. Hachem K, Ansari MJ, Saleh RO, Kzar HH, Al-Gazally ME, Altimari US, Hussein SA, Mohammed HT, Hammid AT, Kianfar E. Methods of chemical synthesis in the synthesis of nanomaterial and nanoparticles by the chemical deposition method: a review. BioNanoScience. 2022 Sep;12(3):1032-57.
13. Kirubakaran D, Wahid JB, Karmegam N, Jeevika R, Sellapillai L, Rajkumar M, SenthilKumar KJ. A comprehensive review on the green synthesis of nanoparticles: advancements in biomedical and environmental applications. Biomedical Materials & Devices. 2025 Feb 24:1-26.
14. Sanati M, Afshari AR, Kesharwani P, Sukhorukov VN, Sahebkar A. Recent trends in the application of nanoparticles in cancer therapy: The involvement of oxidative stress. Journal of Controlled Release. 2022 Aug 1;348:287-304.
15. Mathesvaran T, Senthilkumar SK, Aravind E, Aruna T, Dineshkumar S, Durgadevi M, Thilagavathy P. A REVIEW ON NANOPARTICLES AND ITS APPLICATION.
16. Chandrasekaran K, Kokkarachedu V, Sisubalan N, Vijayan A, Hendry Moses P, Edison Raj Godwin P, Kelvin Adaikalam C, Gowri S, Jason Mathews J, Haja Hameed AS, Ebenezar J. Exploring the medical applications of SnO2 nanomaterials: antimicrobial, antiviral, and anticancer therapies. InNanoparticles in Modern Antimicrobial and Antiviral Applications 2024 Feb 28 (pp. 227-242). Cham: Springer International Publishing.
17. Pinto AH, Nogueira AE, Dalmaschio CJ, Frigini IN, de Almeida JC, Ferrer MM, Berengue OM, Gonçalves RA, de Mendonça VR. Doped tin dioxide (d-SnO2) and its nanostructures: Review of the theoretical aspects, photocatalytic and biomedical applications. Solids. 2022 Jun 2;3(2):327-60.
18. Tripathi D, Pandey P, Sharma S, Rai AK, BH MP. Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity. BioImpacts. 2024 Nov 2;15(1):30573-.

19. Zeng L, Gowda BJ, Ahmed MG, Abourehab MA, Chen ZS, Zhang C, Li J, Kesharwani P. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Molecular Cancer. 2023 Jan 12;22(1):10.
20. Elamin NY, Indumathi T, Kumar ER. Evaluation of physicochemical and biological properties of SnO2 and Fe doped SnO2 nanoparticles. Ceramics International. 2023 Jan 15;49(2):2388-93.
21. Muthulakshmi G, Mohamed Ismail M, Arivanandhan M, Bhaskaran A. Effect of calcination on structural, morphological and electrochemical properties of SnO2 nanoparticles. Journal of Materials Science: Materials in Electronics. 2022 Mar;33(8):5534-51.
22. Ullah E, Shah MZ, Ahmad SA, Sajjad M, Khan S, Alzahrani FM, Yahya AE, Eldin SM, Akkinepally B, Shah A, Guo S. Hydrothermal assisted synthesis of hierarchical SnO2 micro flowers with CdOnanoparticles based membrane for energy storage applications. Chemosphere. 2023 Apr 1;321:138004.
23. Smok W, Tański T. A short review on various engineering applications of electrospun one-dimensional metal oxides. Materials. 2021 Sep 7;14(18):5139.
24. Kumari K, Ahmaruzzaman M. SnO2 quantum dots (QDs): Synthesis and potential applications in energy storage and environmental remediation. Materials Research Bulletin. 2023 Dec 1;168:112446.
25. Kumar M, Saravanan A, Joshi SA, Chen SC, Huang BR, Sun H. High-performance self-powered UV photodetectors using SnO2 thin film by reactive magnetron sputtering. Sensors and Actuators A: Physical. 2024 Aug 1;373:115441.
26. Patel GH, Chaki SH, Kannaujiya RM, Parekh ZR, Hirpara AB, Khimani AJ, Deshpande MP. Sol-gel synthesis and thermal characterization of SnO2 nanoparticles. Physica B: Condensed Matter. 2021 Jul 15;613:412987.
27. Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis and Photodynamic Therapy. 2022 Sep 1;39:102915.
28. Mini JJ, Khan S, Aravind M, Mol T, Bahajjaj AA, Robert HM, Kumaresubitha T, Anwar A, Li H. Investigation of antimicrobial and anti-cancer activity of thermally sensitive SnO2 nanostructures with green-synthesized cauliflower morphology at ambient weather conditions. Environmental Research. 2024 Mar 15;245:117878.
29. Zhang W, Taheri-Ledari R, Ganjali F, Mirmohammadi SS, Qazi FS, Saeidirad M, KashtiAray A, Zarei-Shokat S, Tian Y, Maleki A. Effects of morphology and size of nanoscale drug carriers on cellular uptake and internalization process: a review. RSC advances. 2023;13(1):80-114.
30. Belino WL, Lieb LC, Ferreira JH, Tiba DY, De Souza OP, Abreu TM, Lima Silva FW, Santelli RE, Cincotto FH, Canevari TC. Carbon Nanomaterial-Based Sensor for the Electrocatalytic Detection of Water Pollutants. Topics in Catalysis. 2025 Feb 10:1-8.
31. Ahmad F, Salem-Bekhit MM, Khan F, Alshehri S, Khan A, Ghoneim MM, Wu HF, Taha EI, Elbagory I. Unique properties of surface-functionalized nanoparticles for bio-application: functionalization mechanisms and importance in application. Nanomaterials. 2022 Apr 13;12(8):1333.
32. Ibrahim M, Ramadan E, Elsadek NE, Emam SE, Shimizu T, Ando H, Ishima Y, Elgarhy OH, Sarhan HA, Hussein AK, Ishida T. Polyethylene glycol (PEG): The nature, immunogenicity, and role in

the hypersensitivity of PEGylated products. Journal of Controlled Release. 2022 Nov 1;351:215-30.

33. Biondo F, Baldassarre F, Vergaro V, Ciccarella G. Controlled biocide release from smart delivery systems: Materials engineering to tune release rate, biointeractions, and responsiveness. InNanotechnology-Based Sustainable Alternatives for the Management of Plant Diseases 2022 Jan 1 (pp. 31-147). Elsevier.
34. Ramanathan G, Murali KR. Photocatalytic activity of SnO2 nanoparticles. Journal of Applied Electrochemistry. 2022 May;52(5):849-59.
35. Ray S, Maiti DK. Metal-Oxide-Semiconductor Devices. In2D Semiconducting Materials for Electronic, Photonic, and Optoelectronic Devices 2024 Nov 7 (pp. 116-129). CRC Press.
36. Ahamed M, Akhtar MJ, Khan MM, Alhadlaq HA. SnO2-doped ZnO/reduced graphene oxide nanocomposites: synthesis, characterization, and improved anticancer activity via oxidative stress pathway. International Journal of Nanomedicine. 2021 Jan 8:89-104.Munawar T, Nadeem MS, Mukhtar F, Rehman MN, Riaz M, Batool S, Hasan M, Iqbal F. Transition metal-doped SnO2 and graphene oxide (GO) supported nanocomposites as efficient photocatalysts and antibacterial agents. Environmental Science and Pollution Research. 2022 Dec;29(60):90995-1016.
37. Munawar T, Nadeem MS, Mukhtar F, Rehman MN, Riaz M, Batool S, Hasan M, Iqbal F. Transition metal-doped SnO2 and graphene oxide (GO) supported nanocomposites as efficient photocatalysts and antibacterial agents. Environmental Science and Pollution Research. 2022 Dec;29(60):90995-1016.
38. Li G, Wang C, Jin B, Sun T, Sun K, Wang S, Fan Z. Advances in smart nanotechnology-supported photodynamic therapy for cancer. Cell Death Discovery. 2024 Nov 11;10(1):466.
39. The sol-gel technique is one of the most versatile and widely adopted methods for producing SnO_2 nanoparticles with precise control over size, crystallinity, and surface area
40. Mishra SR, Ahmaruzzaman M. Tin oxide based nanostructured materials: synthesis and potential applications. Nanoscale. 2022;14(5):1566-605.
41. Liu W, Wang S, Wang J, Zhang B, Liu L, Liu H, Yang J. Supercritical hydrothermal synthesis of nano-zinc oxide: Process and mechanism. Ceramics International. 2022 Aug 15;48(16):22629-46.
42. Khan SA, Kanwal S, Rizwan K, Shahid S. Enhanced antimicrobial, antioxidant, in vivo antitumor and in vitro anticancer effects against breast cancer cell line by green synthesized un-doped SnO2 and Co-doped SnO2 nanoparticles from Clerodendrum inerme. Microbial pathogenesis. 2018 Dec 1;125:366-84.
43. Sun L, Yuan G, Gao L, Yang J, Chhowalla M, Gharahcheshmeh MH, Gleason KK, Choi YS, Hong BH, Liu Z. Chemical vapour deposition. Nature Reviews Methods Primers. 2021 Jan 14;1(1):5.
44. Chen Z, Pan D, Li Z, Jiao Z, Wu M, Shek CH, Wu CL, Lai JK. Recent advances in tin dioxide materials: some developments in thin films, nanowires, and nanorods. Chemical reviews. 2014 Aug 13;114(15):7442-86.
45. Sanati M, Afshari AR, Kesharwani P, Sukhorukov VN, Sahebkar A. Recent trends in the application of nanoparticles in cancer therapy: The involvement of oxidative stress. Journal of Controlled Release. 2022 Aug 1;348:287-304.
46. Letifi H, Dridi D, Litaiem Y, Ammar S, Dimassi W, Chtourou R. High efficient and cost effective titanium doped tin dioxide based photocatalysts synthesized via co-precipitation approach. Catalysts. 2021 Jun 30;11(7):803.

47. Kumar R, Dhar A, Banerjee A, Mondal S. Scientific Frontiers: Sustainable Practices and Technologies.
48. Panda S, Hajra S, Kaushik A, Rubahn HG, Mishra YK, Kim HJ. Smart nanomaterials as the foundation of a combination approach for efficient cancer theranostics. Materials Today Chemistry. 2022 Dec 1;26:101182.
49. Kumar A, Chitkara M, Thakur R. Tin oxide nanoparticles: a review. Nanoscience & Nanotechnology-Asia. 2023 Dec 1;13(6):27-36.
50. Huang R, Chen H, Liang J, Li Y, Yang J, Luo C, Tang Y, Ding Y, Liu X, Yuan Q, Yu H. Dual role of reactive oxygen species and their application in cancer therapy. Journal of Cancer. 2021 Jul 25;12(18):5543.
51. Khan SA, Kanwal S, Rizwan K, Shahid S. Enhanced antimicrobial, antioxidant, in vivo antitumor and in vitro anticancer effects against breast cancer cell line by green synthesized un-doped SnO2 and Co-doped SnO2 nanoparticles from Clerodendrum inerme. Microbial pathogenesis. 2018 Dec 1;125:366-84.
52. Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. International journal of molecular sciences. 2020 Mar 28;21(7):2346.
53. Ahamed M, Akhtar MJ, Khan MM, Alhadlaq HA. Oxidative stress mediated cytotoxicity of tin (IV) oxide (SnO2) nanoparticles in human breast cancer (MCF-7) cells. Colloids and Surfaces B: Biointerfaces. 2018 Dec 1;172:152-60.
54. Zhou Z, Arroum T, Luo X, Kang R, Lee YJ, Tang D, Hüttemann M, Song X. Diverse functions of cytochrome c in cell death and disease. Cell Death & Differentiation. 2024 Apr;31(4):387-404.
55. Hanna DH, R. Saad G. Induction of mitochondria mediated apoptosis in human ovarian cancer cells by folic acid coated tin oxide nanoparticles. Plos one. 2021 Oct 1;16(10):e0258115.
56. Guo Y, Zhao Y, Zhao X, Song S, Qian B. Exploring the anticancer effects of tin oxide nanoparticles synthesized by pulsed laser ablation technique against breast cancer cell line through downregulation of PI3K/AKT/mTOR signaling pathway. Arabian Journal of Chemistry. 2021 Jul 1;14(7):103212.
57. Al Bitar S, Gali-Muhtasib H. The role of the cyclin dependent kinase inhibitor p21cip1/waf1 in targeting cancer: Molecular mechanisms and novel therapeutics. Cancers. 2019 Sep 30;11(10):1475.
58. Abdel-Ghany S, Raslan S, Tombuloglu H, Shamseddin A, Cevik E, Said OA, Madyan EF, Senel M, Bozkurt A, Rehman S, Sabit H. Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation. 3 Biotech. 2020 Sep;10:1-4.
59. Almanghadim HG, Nourollahzadeh Z, Khademi NS, Tezerjani MD, Sehrig FZ, Estelami N, Shirvaliloo M, Sheervalilou R, Sargazi S. Application of nanoparticles in cancer therapy with an emphasis on cell cycle. Cell biology international. 2021 Oct;45(10):1989-98.
60. Marzi M, Osanloo M, Vakil MK, Mansoori Y, Ghasemian A, Dehghan A, Zarenezhad E. Applications of metallic nanoparticles in the skin cancer treatment. BioMed Research International. 2022;2022(1):2346941.
61. Zeng L, Gowda BJ, Ahmed MG, Abourehab MA, Chen ZS, Zhang C, Li J, Kesharwani P. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Molecular Cancer. 2023 Jan 12;22(1):10.

62. Shrestha B, Tang L, Romero G. Nanoparticles-mediated combination therapies for cancer treatment. Advanced Therapeutics. 2019 Nov;2(11):1900076.
63. Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, Tong R, Miao YB, Cai L. Smart nanoparticles for cancer therapy. Signal transduction and targeted therapy. 2023 Nov 3;8(1):418.
64. Abdussalam-Mohammed W. Comparison of chemical and biological properties of metal nanoparticles (Au, Ag), with metal oxide nanoparticles (ZnO-NPs) and their applications. Adv J Chem Sect A. 2020;3(2):111-236.
65. Adnane F, El-Zayat E, Fahmy HM. The combinational application of photodynamic therapy and nanotechnology in skin cancer treatment: A review. Tissue and Cell. 2022 Aug 1;77:101856.
66. Allegra A, Pioggia G, Tonacci A, Musolino C, Gangemi S. Oxidative stress and photodynamic therapy of skin cancers: Mechanisms, challenges and promising developments. Antioxidants. 2020 May 22;9(5):448.
67. Li G, Wang C, Jin B, Sun T, Sun K, Wang S, Fan Z. Advances in smart nanotechnology-supported photodynamic therapy for cancer. Cell Death Discovery. 2024 Nov 11;10(1):466.
68. Saindane D, Bhattacharya S, Shah R, Prajapati BG. The recent development of topical nanoparticles for annihilating skin cancer. All Life. 2022 Dec 31;15(1):843-69.
69. Saindane D, Bhattacharya S, Shah R, Prajapati BG. The recent development of topical nanoparticles for annihilating skin cancer. All Life. 2022 Dec 31;15(1):843-69.
70. Almoshari Y. Novel hydrogels for topical applications: An updated comprehensive review based on source. Gels. 2022 Mar 10;8(3):174.
71. Achagar R, Ait-Touchente Z, El Ati R, Boujdi K, Thoume A, Abdou A, Touzani R. A comprehensive review of essential oil–nanotechnology synergy for advanced Dermocosmetic delivery. Cosmetics. 2024 Mar 27;11(2):48.
72. Delgado-Pujol EJ, Martínez G, Casado-Jurado D, Vázquez J, León-Barberena J, Rodríguez-Lucena D, Torres Y, Alcudia A, Begines B. Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems. Pharmaceutics. 2025 Feb;17(2):215.
73. Shelley H, Babu RJ. Role of cyclodextrins in nanoparticle-based drug delivery systems. Journal of pharmaceutical sciences. 2018 Jul 1;107(7):1741-53.
74. Bahmani A, Taghvaei A, Firozian F, Chehardoli G. Folic Acid as an Exploiter of Natural Endocytosis Pathways in Drug Delivery. Chem. Methodologies. 2024 Jan 1;8:96-122.
75. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced drug delivery reviews. 2016 Apr 1;99:28-51.
76. Bogdanović B, Fagret D, Ghezzi C, Montemagno C. Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine–Glycine–Aspartate) Strategies. Pharmaceuticals. 2024 Nov 20;17(11):1556.
77. Khan SA, Kanwal S, Rizwan K, Shahid S. Enhanced antimicrobial, antioxidant, in vivo antitumor and in vitro anticancer effects against breast cancer cell line by green synthesized un-doped SnO2 and Co-doped SnO2 nanoparticles from Clerodendrum inerme. Microbial pathogenesis. 2018 Dec 1;125:366-84.
78. Ahamed M, Akhtar MJ, Khan MM, Alhadlaq HA. SnO2-doped ZnO/reduced graphene oxide nanocomposites: synthesis, characterization, and improved anticancer activity via oxidative stress pathway. International Journal of Nanomedicine. 2021 Jan 8:89-104.

79. Adan A, Kiraz Y, Baran Y. Cell proliferation and cytotoxicity assays. Current pharmaceutical biotechnology. 2016 Nov 1;17(14):1213-21.
80. Mani S, Swargiary G. In vitro cytotoxicity analysis: MTT/XTT, trypan blue exclusion. InAnimal cell culture: principles and practice 2023 Feb 1 (pp. 267-284). Cham: Springer International Publishing.
81. Wahab R, Khan F, Al-Khedhairy AA. Quantization of SnO2 dots: Apoptosis and intrinsic effect of quantum dots for myoblast cancer cells with caspase 3/7 genes. Ceramics International. 2020 Apr 1;46(5):6383-95.
82. Sharma N, Saifi MA, Singh SB, Godugu C. In vivo studies: toxicity and biodistribution of nanocarriers in organisms. InNanotoxicity 2020 Jan 1 (pp. 41-70). Elsevier.
83. Hu Y, Feng L, Zhu Y, Yu C, Zhao R, Ding H, Yang P. Emerging tin-based engineering for tumor treatment: Current advances and forward opportunities. Coordination Chemistry Reviews. 2024 Dec 15;521:216168.
84. Kumar A, Vaiphei KK, Gulbake A. A nanotechnology driven effectual localized lung cancer targeting approaches using tyrosine kinases inhibitors: Recent progress, preclinical assessment, challenges, and future perspectives. International Journal of Pharmaceutics. 2024 Sep 23:124745.
85. Sutomo DF, Ahsani DN, Fidianingsih I. Toxicity of nanoparticles on the spleen in animal studies: A scoping review. JurnalIlmuKefarmasian Indonesia. 2022 Oct 30;20(2):158-68.
86. Chavali MS, Nikolova MP. Metal oxide nanoparticles and their applications in nanotechnology. SN applied sciences. 2019 Jun;1(6):607.
87. Chavali MS, Nikolova MP. Metal oxide nanoparticles and their applications in nanotechnology. SN applied sciences. 2019 Jun;1(6):607.
88. Li H, Li Q, Li Y, Sang X, Yuan H, Zheng B. Stannic oxide nanoparticle regulates proliferation, invasion, apoptosis, and oxidative stress of oral cancer cells. Frontiers in Bioengineering and Biotechnology. 2020 Jul 17;8:768.
89. Gautam A. *Interaction of TiO2 and ZnO NPs with human skin cells* (Doctoral dissertation).
90. Hanna DH, R. Saad G. Induction of mitochondria mediated apoptosis in human ovarian cancer cells by folic acid coated tin oxide nanoparticles. Plos one. 2021 Oct 1;16(10):e0258115.
91. Bamagous GA, Ibrahim IA, Alzahrani AR, Shahid I, Shahzad N, Falemban AH, Alanazi IM, Hussein-Al-Ali SH, Arulselvan P, Thangavelu I. Multifunctional SnO_2-Chitosan-D-carvone Nanocomposite: A Promising Antimicrobial, Anticancer, and Antioxidant Agent for Biomedical Applications. Journal of Inorganic and Organometallic Polymers and Materials. 2024 Nov 5:1-7.
92. Furtado RA, Ozelin SD, Ferreira NH, Miura BA, Almeida Junior S, Magalhães GM, Nassar EJ, Miranda MA, Bastos JK, Tavares DC. Antitumor activity of solamargine in mouse melanoma model: Relevance to clinical safety. Journal of Toxicology and Environmental Health, Part A. 2022 Feb 16;85(4):131-42.
93. Feng L, Zhao R, Liu B, He F, Gai S, Chen Y, Yang P. Near-infrared upconversion mesoporous tin oxide bio-photocatalyst for H2O2-activatable O2-generating magnetic targeting synergetic treatment. ACS Applied Materials & Interfaces. 2020 Aug 20;12(37):41047-61.
94. Saddick S. Nanomedicine for ovarian cancer: Enhancing pharmacokinetics and biodistribution. Journal of King Saud University-Science. 2024 Dec 4:103584.

95. Wei Q, Kong N, Liu X, Tian R, Jiao M, Li Y, Guan H, Wang K, Yang P. Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro. Journal of Translational Medicine. 2021 Dec;19:1-2.
96. Alshammari GM, Al-Ayed MS, Abdelhalim MA, Al-Harbi LN, Yahya MA. Effects of antioxidant combinations on the renal toxicity induced rats by gold nanoparticles. Molecules. 2023 Feb 16;28(4):1879.
97. Anjum S, Hashim M, Malik SA, Khan M, Lorenzo JM, Abbasi BH, Hano C. Recent advances in zinc oxide nanoparticles (ZnO NPs) for cancer diagnosis, target drug delivery, and treatment. Cancers. 2021 Sep 12;13(18):4570.
98. Zak AK, Zak HK, Esmaeilzadeh J. Cytotoxicity Studies of Ultra-Fine NiO Nanoparticles on HeLa and GC-1spg Cell Lines: A Promising Materials for Cancer Treatment Application. Ceramics International. 2025 Jan 27.
99. Etafa Y, Krishnaraj R, Saka A. Exploring the synthesis, characterization and the different Potential applications of SnO2 and TiO2 Nanoparticles: A Comprehensive Review. Journal of Science, Technology and Arts Research. 2024 Sep 30;13(3):R1-4.
100. Abbasi R, Shineh G, Mobaraki M, Doughty S, Tayebi L. Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. Journal of Nanoparticle Research. 2023 Mar;25(3):43.
101. Mu Q, Jiang G, Chen L, Zhou H, Fourches D, Tropsha A, Yan B. Chemical basis of interactions between engineered nanoparticles and biological systems. Chemical reviews. 2014 Aug 13;114(15):7740-81.
102. Tamilselvi R, Nandhini S, Muniyandi E, Saravanakumar P, Venkatesh A, Prakash V. Cytotoxicity of Metals and Metal Oxides Nanoparticles in Dentistry: A Comprehensive Review. Biomedical and Pharmacology Journal. 2025 Mar 31;18(1):471-81.
103. Golbamaki N, Rasulev B, Cassano A, Robinson RL, Benfenati E, Leszczynski J, Cronin MT. Genotoxicity of metal oxide nanomaterials: review of recent data and discussion of possible mechanisms. Nanoscale. 2015;7(6):2154-98.
104. Thakur A, Kumar A. Strategies for Enhancing Biocompatibility of Nanoparticles. Nanoparticle Toxicity and Compatibility. 2024 Mar 15;161:182-224.
105. Zhang H, Shan Y, Dong L. A comparison of TiO2 and ZnO nanoparticles as photosensitizers in photodynamic therapy for cancer. Journal of biomedical nanotechnology. 2014 Aug 1;10(8):1450-7.
106. Khan N, Ali Shah S, Hubab M, Tul Muntaha S, Khan I, Hayat A, Ur Rehman M, Shah TA, Bensalah J, Gaafar AR, Dauelbait M. Synthesis, characterization, and antibacterial activities of SnO and SnO@ FeCl2 nanoparticles using Olea europaea subsp. Africana (Mill.) PS Green mediated green. CyTA-Journal of Food. 2025 Dec 31;23(1):2421787.
107. Taleuzzaman M, Jahangir MA, Chauhan S, Kala C, Beg S. Good laboratory practice and current good manufacturing practice requirements in the development of cancer nanomedicines. InNanoformulation Strategies for Cancer Treatment 2021 Jan 1 (pp. 341-352). Elsevier.
108. Liggitt HD. Evaluation of Biodistribution, Toxicology, and Toxicologic Pathology of Nanomaterials Used to Deliver Nucleic Acids. Nanotechnology Characterization Tools for Environment, Health, and Safety. 2019:65-102.

109. Resnik DB, Tinkle SS. Ethical issues in clinical trials involving nanomedicine. Contemporary clinical trials. 2007 Jul 1;28(4):433-41.
110. Sen A, Kumar K, Khan S, Pathak P, Singh A. Current Therapy in Cancer: Advances, Challenges, and Future Directions. Asian Journal of Nursing Education and Research. 2024;14(1):77-84.
111. Chandrasekaran K, Kokkarachedu V, Sisubalan N, Vijayan A, Hendry Moses P, Edison Raj Godwin P, Kelvin Adaikalam C, Gowri S, Jason Mathews J, Haja Hameed AS, Ebenezar J. Exploring the medical applications of SnO2 nanomaterials: antimicrobial, antiviral, and anticancer therapies. InNanoparticles in Modern Antimicrobial and Antiviral Applications 2024 Feb 28 (pp. 227-242). Cham: Springer International Publishing.
112. Pan Y, Xue X, Liang XJ. Nanotechnology-Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives. Advanced NanoBiomed Research. 2024 Apr;4(4):2300129.
113. Singh V. Theranostics: Integrated Diagnostics and Therapy Using Nanomedicine. InNanomedicine 2024 (pp. 505-530). Springer, Cham.
114. Abdel-Latif HM, Shukry M, El Euony OI, Mohamed Soliman M, Noreldin AE, Ghetas HA, Dawood MA, Khallaf MA. Hazardous effects of SiO2 nanoparticles on liver and kidney functions, histopathology characteristics, and transcriptomic responses in Nile Tilapia (Oreochromis niloticus) Juveniles. Biology. 2021 Mar 2;10(3):183.
115. Tamilselvi R, Nandhini S, Muniyandi E, Saravanakumar P, Venkatesh A, Prakash V. Cytotoxicity of Metals and Metal Oxides Nanoparticles in Dentistry: A Comprehensive Review. Biomedical and Pharmacology Journal. 2025 Mar 31;18(1):471-81.